VUNO Med®-DeepBrain™

It parcellates the brain into 100+ parts using 3D T1 non-contrast MRI and provides quantitative data describing volume, normative percentiles, and cortical thickness with color overlays. The solution assists the diagnosis of neurodegenerative disorders by analyzing the atrophy of main brain structures.
Information source: Vendor
Last updated: Oct. 26, 2023

General Information

Product name VUNO Med®-DeepBrain™
Company VUNO
Subspeciality Neuro
Modality MR
Disease targeted Atrophy, Dementia
Key-features Brain parcellation, Atrophy quantification
Suggested use During: perception aid (prompting all abnormalities/results/heatmaps), interactive decision support (shows abnormalities/results only on demand), report suggestion

Technical Specifications

Data characteristics
Population Population with a risk of brain atrophy
Input 3D T1 Brain MRI
Input format DICOM
Output Parcellation of whole brain in 100 parts, Quantification of atrophy, Normal comparison
Output format DICOM, NIFTI, PDF
Integration Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform, Stand-alone third party application, Stand-alone webbased
Deployment Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based, Hybrid solution
Trigger for analysis Automatically, right after the image acquisition
Processing time 10 - 60 seconds


Certified, Class IIa , MDD
FDA 510(k) cleared , Class II
Intended Use Statements
Intended use (according to CE)


Market presence
On market since 06-2020
Distribution channels
Countries present (clinical, non-research use) 10+
Paying clinical customers (institutes)
Research/test users (institutes)
Pricing model Pay-per-use
Based on Number of analyses


Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers